Efficacy News and Research

RSS

Imaxio awarded ANR funding to improve efficacy of vaccines for seasonal influenza

Imaxio, a biopharmaceutical company specialized in vaccines, today announces that it has been awarded funding of EUR 600,000 (USD 772,000) by the French National Research Agency (Agence Nationale de la Recherche, ANR) for the OPTIVAC project 'leveraging On t-cell immune resPonse To Improve influenza VACcines'.

28 Oct 2014

Clementia initiates Phase 2 extension study of palovarotene in FOP patients

Clementia Pharmaceuticals, Inc. announced today the initiation of a Phase 2 extension study of palovarotene in patients with fibrodysplasia ossificans progressiva (FOP), a rare, severely disabling genetic disease characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) and new abnormal bone formation.

27 Oct 2014

Researchers to explore new treatment strategies using blood plasma from Ebola survivors

The University of Liverpool is part of an international research team that will assess whether the blood or plasma of Ebola survivors can be used to treat Ebola patients in West Africa.

27 Oct 2014

WHO holds meeting to discuss on how to fast track testing, deployment of Ebola vaccines

WHO convened a meeting with high-ranking government representatives from Ebola-affected countries and development partners, civil society, regulatory agencies, vaccine manufacturers and funding agencies yesterday to discuss and agree on how to fast track testing and deployment of vaccines in sufficient numbers to impact the Ebola epidemic.

26 Oct 2014

Mindfulness improves cardiovascular health

Pay attention to the implication of these new research results: People who pay more attention to their feelings and experiences tend to have better cardiovascular health.

25 Oct 2014

Medicinal plant market goes untested for health hazards, shows study

Medicinal plant market goes untested for health hazards, according to a recent study published in journal Fungal Biology

24 Oct 2014

electroCore’s gammaCore device effective for treating migraines, shows trial results

Preliminary results of an open-label trial carried in the journal of Headache and Pain reported that a single treatment with electroCore’s hand held non-invasive vagus nerve stimulation (nVNS) device gammaCore, completely resolved 44.8% of migraines within 30 minutes, with an additional 11.4% experiencing moderate benefits (incomplete resolution of their headaches) by 2 hours.

24 Oct 2014

ADI develops ELISA test kits for detection of Ebola viral protein antibodies

San Antonio, Texas-based Biotech Company Alpha Diagnostic Int'l has developed and released several convenient, rapid, and sensitive ELISA test kits for the detection of major Ebola viral protein antibodies (Glycoprotein, GP; Nucleoprotein, NP, and Viral Protein 40 or VP40).

23 Oct 2014

Afatinib active against NSCLC nervous system metastases

Heavily pretreated patients with epidermal growth factor receptor-mutated non-small-cell lung cancer and central nervous system metastases may benefit from treatment with afatinib, say German researchers.

22 Oct 2014

Regulus Therapeutics demonstrates human proof-of-concept with microRNA therapeutic

Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has demonstrated human proof-of-concept with a microRNA therapeutic from an ongoing clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 (“miR-122”), for the treatment of hepatitis C virus infection (“HCV”).

22 Oct 2014

RegeneRx to begin RGN-259 Phase 3 trials for treatment of neurotrophic keratopathy

RegeneRx Biopharmaceuticals, Inc. ("the Company" or "RegeneRx") today announced that it met with the FDA in September and as a result of the meeting may begin Phase 3 to evaluate RGN-259 preservative-free eye drops for the treatment of patients with neurotrophic keratopathy (NK), an orphan disease of the cornea.

20 Oct 2014

Aspirin can improve efficacy of schizophrenia treatments

A new study shows that some anti-inflammatory medicines, such as aspirin, estrogen, and Fluimucil, can improve the efficacy of existing schizophrenia treatments. This work is being presented at the European College of Neuropsychopharmacology conference in Berlin.

20 Oct 2014

Study identifies five major disruptors that can negatively impact medical device industry

The medical device industry has enjoyed stability, strong growth, healthy margins and above average price-to-earnings ratios over the last 20 years.

20 Oct 2014

NIH announces 11 awards to improve public health outcomes related to substance use, addiction

More than $11 million over three years will be used to support research exploring the use of social media to advance the scientific understanding, prevention, and treatment of substance use and addiction.

20 Oct 2014

Regeneron, Sanofi announce initiation of dupilumab Phase 3 study in adults with atopic dermatitis

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis (AD) that is not adequately controlled with topical AD medications.

20 Oct 2014

New drug naming system to be presented at ECNP conference in Berlin

What's in a name? Doctors have found that the name of the drug you are prescribed significantly influences how the patient sees the treatment.

20 Oct 2014

New corneal inlay device offers potential treatment option for presbyopia

A thin ring inserted into the eye could soon offer a reading glasses-free remedy for presbyopia, the blurriness in near vision experienced by many people over the age of 40, according to a study released today at AAO 2014, the 118th annual meeting of the American Academy of Ophthalmology.

20 Oct 2014

Anti-cancer nanomedicines with smaller sizes exhibit enhanced performance in vivo, show studies

Nanomedicines consisting of nanoparticles for targeted drug delivery to specific tissues and cells offer new solutions for cancer diagnosis and therapy.

17 Oct 2014

Researchers receive NIH grant to study mechanisms of auditory hypersensitivity in fragile X syndrome

Fragile X syndrome (FXS) is a genetic disorder in humans that causes social impairments and repetitive behaviors, and other behaviors on the autistic spectrum, as well as cognitive deficits.

17 Oct 2014

Imaxio, DKFZ partner to evaluate potential of IMX313 with candidate vaccine targeting HPV

Imaxio, a biopharmaceutical company specialized in vaccines, today announces that it has signed an option for a license agreement with the world-renowned German Center for Cancer Research (DKFZ – Deutsches Krebsforschungszentrum), based in Heidelberg. The financial terms of the agreement were not disclosed.

15 Oct 2014

Efficacy News and Research

Imaxio awarded ANR funding to improve efficacy of vaccines for seasonal influenza

Clementia initiates Phase 2 extension study of palovarotene in FOP patients

Researchers to explore new treatment strategies using blood plasma from Ebola survivors

WHO holds meeting to discuss on how to fast track testing, deployment of Ebola vaccines

Mindfulness improves cardiovascular health

Medicinal plant market goes untested for health hazards, shows study

electroCore’s gammaCore device effective for treating migraines, shows trial results

ADI develops ELISA test kits for detection of Ebola viral protein antibodies

Afatinib active against NSCLC nervous system metastases

Regulus Therapeutics demonstrates human proof-of-concept with microRNA therapeutic

RegeneRx to begin RGN-259 Phase 3 trials for treatment of neurotrophic keratopathy

Aspirin can improve efficacy of schizophrenia treatments

Study identifies five major disruptors that can negatively impact medical device industry

NIH announces 11 awards to improve public health outcomes related to substance use, addiction

Regeneron, Sanofi announce initiation of dupilumab Phase 3 study in adults with atopic dermatitis

New drug naming system to be presented at ECNP conference in Berlin

New corneal inlay device offers potential treatment option for presbyopia

Anti-cancer nanomedicines with smaller sizes exhibit enhanced performance in vivo, show studies

Researchers receive NIH grant to study mechanisms of auditory hypersensitivity in fragile X syndrome

Imaxio, DKFZ partner to evaluate potential of IMX313 with candidate vaccine targeting HPV

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News